Access, Ideas, Clarity
A leading virtual platform providing investors with direct access to innovative companies, management teams and thought leaders
What This Means:
This series is designed to provide investors with context to press releases directly from company management teams. It also provides the opportunity for companies to communicate directly to investors and elaborate on recent key news and highlight value driving milestones.
September 16, 2024
Wally Klemp, CEO of Moleculin, discusses the Company’s recent update on the Phase 2 clinical trial of STAT3 inhibitor in combination with radiation for the treatment of glioblastoma
_Logo_HOR.png){kind=logo}
July 31, 2024
Mitch Jones, MD, PhD, CMO of Palisade Bio highlights recent findings from a microbiome study confirming local bioactivation of lead product candidate, PALI-2108
July 24, 2024
Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study
July 18, 2024
Brad Hauser, Chief Executive Officer of Autonomix, discusses the Company’s agreement to license FDA-cleared ablation technology from RF Innovations, Inc.
July 11, 2024
Marc Hertz, PhD, CEO of GRI Bio underscores importance of the interim data from their ongoing Phase 2a biomarker study for Idiopathic Pulmonary Fibrosis (IPF)
_Logo_HOR.png){kind=logo}
July 3, 2024
Preliminary Positive Results from the First Five “Lead-in” Patients in the Company’s Ongoing Human Clinical Trial
July 1, 2024
Palisade Bio’s Lead Product Candidate PALI-2018 Demonstrates Positive Preclinical Data
May 22, 2024
Positive Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs
April 25, 2024
The Annamycin Opportunity
May 23, 2024
Autonomix Preclinical Study Successfully Demonstrates That Nerve Ablation Can Slow Tumor Metastasis in Pancreatic Cancer
April 25, 2024
March 15, 2024
ReElement Technologies' Certificate of Occupancy for Marion, Indiana Critical Mineral Refining Supersite
Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve® Pivotal Trial
February 29, 2024
A Major Inflection Point - The Moleculin Opportunity in 2024 and Beyond Series (Part 3 of 3)
February 15, 2024
February 22, 2024
A Major Inflection Point - The Moleculin Opportunity in 2024 and Beyond Series (Part 2 of 3)
A Major Inflection Point - The Moleculin Opportunity in 2024 and Beyond Series (Part 1 of 3)
February 12, 2024
Xenetic Biosciences Highlights Encouraging Recently Reported Preclinical Data on Innovative DNase I Oncology Platform
January 31, 2024
$8,000,000 Transaction for Exclusive Worldwide Rights to Technology for Cardiology Field Use –
Over 100 patents in portfolio
February 09, 2024
AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
_Logo_HOR.png){kind=logo}
January 29, 2024
Palisade Bio Reports Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn's & Colitis Congress
January 9, 2024
American Resources Corporation's ReElement Technologies Adds Former United States Ambassador Mark Gilbert to Board of Directors
January 4, 2024
Morphogenesis, Inc. Announces Corporate Rebranding to TuHURA Biosciences, Inc. and Provides a
Business Overview
January 3, 2024
American Resources Corporation's ReElement Technologies Adds Former CIA Senior Executive Kevin Higgins to Board of Directors